Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Receivables (2023 - 2025)

CG Oncology (CGON) has disclosed Receivables for 3 consecutive years, with $688000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables changed N/A year-over-year to $688000.0, compared with a TTM value of $688000.0 through Dec 2025, changed N/A, and an annual FY2025 reading of $688000.0, changed N/A over the prior year.
  • Receivables was $688000.0 for Q4 2025 at CG Oncology, up from $515000.0 in the prior quarter.
  • Across five years, Receivables topped out at $688000.0 in Q4 2025 and bottomed at $92000.0 in Q4 2023.
  • Average Receivables over 3 years is $334250.0, with a median of $263500.0 recorded in 2024.
  • Peak annual rise in Receivables hit 275.91% in 2025, while the deepest fall reached 125.49% in 2025.
  • Year by year, Receivables stood at $92000.0 in 2023, then soared by 48.91% to $137000.0 in 2024, then skyrocketed by 402.19% to $688000.0 in 2025.
  • Business Quant data shows Receivables for CGON at $688000.0 in Q4 2025, $515000.0 in Q3 2025, and $562000.0 in Q2 2025.